Atypical Teratoid Rhabdoid Tumor (ATRT) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Atypical Teratoid Rhabdoid Tumor (ATRT) is an uncommon and highly aggressive embryonal central nervous system (CNS) tumor typically found in children under 3. ATRT carries a grim prognosis, with most pediatric cases having a reported median survival of only 6 to 12 months. These tumors' rapid growth leads to the onset of ATRT symptoms, which can manifest within days or weeks. These symptoms encompass:
1.
Morning headaches upon waking
2.
Hydrocephalus is characterized by an
accumulation of brain fluid, potentially causing enlarged heads in infants or
headaches and vomiting in older children
3.
Nausea and vomiting are typically worse in the
morning and improve throughout the day
4.
Lethargy and fatigue
5.
Balance and coordination difficulties
Pathologically,
ATRTs display characteristics similar to primitive neuroectodermal tumors
(PNETs), including necrosis with a high rate of mitotic activity and rhabdoid
cells. The majority of ATRTs also exhibit a loss of INI-1 nuclear staining.
These tumors can emerge in various CNS locations and may spread to the spinal
cord. Additionally, ATRTs can develop outside the CNS, for example, in the
kidney. ATRTs originate from various young embryonal cells, encompassing
rhabdoid, neuroepithelial, epithelial, and mesenchymal cells. The rarity of
ATRTs among adults often results in delayed diagnosis, as they are less
frequently considered in the differential diagnosis when compared to more
common tumors.
Thelansis’s
“Atypical Teratoid Rhabdoid Tumor (ATRT) Market Outlook, Epidemiology,
Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers
disease overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Atypical
Teratoid Rhabdoid Tumor (ATRT) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Atypical Teratoid
Rhabdoid Tumor (ATRT) across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Atypical
Teratoid Rhabdoid Tumor (ATRT) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Tags: Atypical
Teratoid Rhabdoid Tumor (ATRT), Atypical Teratoid Rhabdoid Tumor (ATRT) market outlook, Atypical Teratoid Rhabdoid Tumor
(ATRT) competitive landscape, Atypical
Teratoid Rhabdoid Tumor (ATRT) market forecast,
Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)
Comments
Post a Comment